Clinical Trial Update: Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of Sullumab and Fruquintinib as postoperative adjuvant therapy for high-risk non-clear cell renal cell carcinoma; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-clear Cell Renal Cell Carcinoma

Drugs mentioned

• Fruquintinib (fruquintinib)
• Sullumab

Snippet

Sponsor: Sun Yat-sen University | Conditions: Non-Clear Cell Renal Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING